Skip to main content

Welcome to the Highmark Health organization of leading health care companies and more than 35,000 employees.

We're proud to serve over 50 million Americans in all 50 states and the District of Columbia through our businesses in health insurance, health care delivery, post-acute care management solutions, managed vision care, retail eyewear and eye care services, eyewear manufacturing, dental solutions, health risk solutions and innovative technology-based solutions.

We share a deep commitment to improving the health care system, the health of our local communities and the health care experience of those we serve. We invite you to learn more.

Our Innovation

Health care requires new ideas and new thinking on a daily basis

We believe that value-driven medicine is likely to be realized in integrated systems where payers and providers are aligned, share a common patient-centered mission and work together to develop products and solutions that address what consumers really want and need.

Highmark Health is dedicated to innovation that makes a positive impact on our customers, with a focus on fast tracking life-saving treatments and business processes that improve our customers' quality of life and exceed their expectations. Partnerships — both internal and external — with industry-leading experts position our two established programs for success:

Disruptive Health Technology Institute

The Carnegie Mellon University Disruptive Health Technology Institute (DHTI) leverages science and engineering to create transformational improvements in the affordability, accessibility, quality and simplicity of health care solutions.

DHTI is an innovation ecosystem that provides full research and development capabilities and continuity from basic research through patient deployment by leveraging experienced principal investigators at CMU partnered with thought leaders at Highmark Inc. and clinicians at the Allegheny Health Network.

Launched in 2012, DHTI focuses on three specific paths to driving innovation:

  • Combining claims data, data-mining, machine learning, predictive modeling, devices and technology development;
  • Payer and provider expertise guidance;
  • Patient-focused clinical testing and deployment.

Since its inception, DHTI has received 119 proposals from engineering (40), computer science (50), basic sciences (17) and the Business School and Decision Sciences programs (12).

For additional information, visit DHTI's website.

VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovation Program

One of the reasons new therapies take a long time to reach patients is that FDA approved technologies often lack sufficient scientific proof to convince health care payers to reimburse for them. The VITAL program's goal is to facilitate the early use of new technologies and look at both their clinical and cost effectiveness from the patient's perspective. This should naturally lead to important evidence that could support a reimbursement decision.

VITAL's mission is to leverage Highmark Health's position as one of the largest integrated health care delivery and financing systems in the nation to accelerate the pace with which novel technologies and services are made available to our customers. In doing so:

  • Members and patients will be afforded access to safe new technologies without undue financial burden.
  • Payers will be able to understand the full impact of new technologies on their members without changing insurance medical policy prematurely.
  • Providers will gain early access to novel technologies and a first-hand understanding of their impact on patients.
  • Technology vendors will have the opportunity to prove the benefits of their new innovations to patients, providers and payers.

Through VITAL, we have built a process where innovators have an opportunity to describe their ideas in depth to the VITAL Review Board, support them with existing knowledge, identify knowledge gaps and submit a proposal for a pilot project or a clinical trial seeking to close those gaps. Akin to the Centers for Medicaid & Medicare Services' (CMS) coverage with evidence development policy, the VITAL Committee makes its decisions to cover the costs of an item or service only in the context of an approved project and for the duration of that project following a formal, rigorous review. If the study meets the agreed targets, the technology may be considered for medical reimbursement.

For additional information, visit VITAL's website.